口服纳布啡治疗特发性肺纤维化相关咳嗽:CORAL随机临床试验
这项在10个国家52个中心开展的随机、双盲、安慰剂对照2b期试验纳入165例特发性肺纤维化相关慢性咳嗽患者,比较纳布啡缓释剂27mg、54mg、108mg每日两次与安慰剂治疗6周的效果。结果显示三个剂量组均降低客观咳嗽频率,两个较高剂量组改善患者报告的咳嗽频率。
要点
- 纳布啡缓释剂27mg、54mg、108mg每日两次均较安慰剂降低24小时客观咳嗽频率。
- 54mg和108mg组患者报告的咳嗽频率较安慰剂改善,27mg组未达统计学显著。
- 研究纳入特发性肺纤维化伴慢性咳嗽至少8周且咳嗽严重程度评分≥4分的患者。
核心结论
- 对于特发性肺纤维化相关慢性咳嗽患者,纳布啡缓释剂三个剂量均降低6周时客观咳嗽频率,两个较高剂量改善患者报告的咳嗽频率。
研究设计与样本
- 随机、双盲、安慰剂对照2b期试验,在10个国家52个中心开展,2024年2月至2025年2月入组,末次随访至2025年4月,统计分析于2025年5月至8月进行。
- 筛查223例,随机165例(纳布啡缓释剂27mg组42例、54mg组43例、108mg组40例、安慰剂组40例),160例纳入主要分析;中位年龄71岁(范围51-85岁),女性占28.5%。
- 患者按1:1:1:1随机接受纳布啡缓释剂27mg、54mg、108mg或安慰剂每日两次,治疗6周。
主要发现
- 基线平均(SD)咳嗽计数为28.3(27.4)次/小时。
- 第6周24小时咳嗽频率相对基线平均相对下降:27mg组47.9%(从24.6降至11.9次/小时,P=0.008)、54mg组53.4%(从28.0降至14.9次/小时,P<0.001)、108mg组60.2%(从31.5降至11.9次/小时,P<0.001),安慰剂组为16.9%(从29.4降至28.1次/小时)。
- 第6周患者报告咳嗽频率相对基线变化:27mg组-31.4%(从2.3降至1.5,P=0.14)、54mg组-40.6%(从2.6降至1.4,P=0.004)、108mg组-40.2%(从2.4降至1.4,P<0.005),安慰剂组为-21.9%(从2.6降至1.9)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: For patients with idiopathic pulmonary fibrosis (IPF), cough impairs quality of life; effective treatments for IPF-associated cough are needed. OBJECTIVE: To determine if nalbuphine extended release (ER), a κ opioid receptor agonist and μ-opioid receptor antagonist, decreases cough compared with placebo in patients with IPF-associated cough. DESIGN, SETTING, AND PARTICIPANTS: In this randomized, double-blind, placebo-controlled phase 2b trial conducted at 52 sites in 10 countries, patients with IPF, chronic cough for at least 8 weeks, and a Cough Severity Numerical Rating Scale (0, no cough; 10, worst possible cough) score of 4 or higher were enrolled from February 2024 to February 2025, with last follow-up in April 2025. Statistical analyses were conducted from May to August 2025. INTERVENTION: Patients were randomized 1:1:1:1 to receive nalbuphine ER at doses of 27 mg, 54 mg, or 108 mg or placebo twice daily for 6 weeks. MAIN OUTCOMES AND MEASURES: The primary outcome was the relative change from baseline in 24-hour cough frequency (coughs/h), measured with a digital cough monitor, for nalbuphine ER compared with placebo at week 6. The key secondary outcome was the relative change from baseline in the patient-reported cough frequency (Evaluating Respiratory Symptoms in IPF cough subscale; scores range from 0-4, lower scores indicate lesser cough frequency) at week 6. RESULTS: Of the 223 patients screened, 165 were randomized (42, 43, 40, and 40 to receive nalbuphine ER 27 mg, 54 mg, and 108 mg, and placebo, respectively) and 160 were included in the primary analysis (median age, 71 [range, 51-85] years; 28.5% female). The baseline mean (SD) cough count was 28.3 (27.4) coughs/h. In the nalbuphine ER 27 mg, 54 mg, and 108 mg twice-daily groups, the mean relative decrease in the cough count and the absolute decrease in coughs/h were 47.9% (from 24.6 to 11.9; P = .008), 53.4% (from 28.0 to 14.9; P < .001), and 60.2% (from 31.5 to 11.9; P < .001), respectively, compared with placebo (16.9%; from 29.4 to 28.1 coughs/h). For the key secondary outcome of patient-reported cough frequency at week 6, the relative and absolute changes were -31.4% (from 2.3 to 1.5; P = .14), -40.6% (from 2.6 to 1.4; P = .004), and -40.2% (from 2.4 to 1.4; P < .005) in the 27-mg, 54-mg, and 108-mg groups, respectively, compared with -21.9% (from 2.6 to 1.9) with placebo. CONCLUSIONS AND RELEVANCE: For patients with IPF-associated chronic cough, all 3 doses of nalbuphine ER reduced objective cough frequency and the 2 higher doses improved patient-reported cough frequency at 6 weeks. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT05964335.
引用
- Molyneaux PL, Mogulkoc N, Gunen H, et al. Oral Nalbuphine in Idiopathic Pulmonary Fibrosis-Associated Cough: The CORAL Randomized Clinical Trial. JAMA. 2026. PMID: 41569557. doi:10.1001/jama.2025.26179
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。